Adaptimmune Therapeutics PLC (ADAP) is a publicly traded company in the Unknown sector. Across all available filings, 30 corporate insiders have executed 230 transactions totaling $574.4M, demonstrating a bullish sentiment with $479.5M in net insider flow. The most recent transaction on Sep 2, 2025 involved a sale of 96,000 shares valued at $960.
No significant insider buying has been recorded for ADAP in the recent period.
No significant insider selling has been recorded for ADAP in the recent period.
Based on recent SEC filings, insider sentiment for ADAP is bullish with an Insider Alignment Score of 92/100 and a net flow of $479.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Adaptimmune Therapeutics PLC (ADAP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 30 insiders are actively trading ADAP stock, having executed 230 transactions in the past 90 days. The most active insider is Forest Baskett (Executive), who has made 9 transactions totaling $54.1M.
Get notified when executives and directors at ADAP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Wood Gavin | Executive | Sale | 96,000 | $0.01 | $960 | |
| Aug 28, 2025 | C. Bertrand William Jr | Executive | Sale | 207,000 | $0.01 | $2.1K | |
| Aug 18, 2025 | Behbahani Ali | Executive | Sale | 14,671,794 | $0.01 | $146.7K | |
| Aug 15, 2025 | Behbahani Ali | Executive | Sale | 4,828,206 | $0.01 | $48.3K | |
| Jul 30, 2025 | Llc Ecor1 Capital, | Executive | Sale | 27,433,338 | $0.10 | $2.7M | Large |
| Jul 29, 2025 | Llc Ecor1 Capital, | Executive | Sale | 2,687,460 | $0.10 | $268.7K | |
| Jul 28, 2025 | Llc Ecor1 Capital, | Executive | Sale | 33,931,740 | $0.11 | $3.7M | Large |
| Jun 18, 2024 | Piccina Cintia | Executive | Sale | 24,531 | $0.93 | $22.8K | |
| Jan 17, 2024 | C. Bertrand William Jr | Executive | Sale | 5,309 | $0.67 | $3.6K | |
| Jan 17, 2024 | C. Bertrand William Jr | Executive | Sale | 13,599 | $0.67 | $9.1K | |
| Jan 17, 2024 | Lunger John | Executive | Sale | 12,805 | $0.67 | $8.6K | |
| Jan 17, 2024 | Lunger John | Executive | Sale | 5,309 | $0.67 | $3.6K | |
| Jan 17, 2024 | Norry Elliot | Executive | Sale | 12,967 | $0.67 | $8.7K | |
| Jan 17, 2024 | Norry Elliot | Executive | Sale | 5,309 | $0.67 | $3.6K | |
| Jan 17, 2024 | Rawcliffe Adrian | Executive | Sale | 30,080 | $0.67 | $20.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 103 | $527.0M | 91.6% |
Sale(S) | 122 | $47.5M | 8.3% |
Exercise(M) | 2 | $533.8K | 0.1% |
Award(A) | 3 | $0 | 0.0% |
Insiders at Adaptimmune Therapeutics PLC are accumulating shares at an accelerated pace. With 30 insiders making 230 transactions totaling $527.0M in purchases versus $47.5M in sales, the net buying activity of $479.5M signals strong executive confidence. Forest Baskett (Executive) leads the buying activity with $54.1M in transactions across all time.